Developer site: The content shown here is test data.

Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Back to skin conditions

Optic nerve glioma primary prevention

Introduction

Overview

Overview

Effective measures for the primary prevention of optic nerve glioma include regular eye exams in patients with neurofibromatosis type 1.

Primary Prevention

Primary Prevention

  • Optic pathway glioma occurs in 15 percent of patients with neurofibromatosis 1. Regular eye exams may allow early diagnosis of these tumors before they cause symptoms.
  • Ophthalmologic screening should include confrontation visual field testing, color vision testing, visual acuity testing, and assessment of pupils, eyelids, irises, fundi, and extraocular motility.
  • The evaluation should begin when neurofibromatosis type 1 first is suspected and should be repeated at annual intervals or when symptoms develop. Clinical evaluation in patients with NF-1 appears to be more useful to detect complications than are screening investigations in asymptomatic patients.[1][2]
  • The optimal care for individuals with NF1 aims at the symptomatic treatment and early detection of complications as they occur. Genetic counseling may be advised for people with neurofibromatosis type 1. All children with NF1 should undergo regular growth assessments using standard growth charts.[3]
References

References

  1. ↑ Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE; et al. (1997). “The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2”. JAMA. 278 (1): 51–7. PMIDΒ 9207339.
  2. ↑ Wolkenstein P, FrΓ¨che B, Zeller J, Revuz J (1996). “Usefulness of screening investigations in neurofibromatosis type 1. A study of 152 patients”. Arch Dermatol. 132 (11): 1333–6. PMIDΒ 8915311.
  3. ↑ Clementi M, Milani S, Mammi I, Boni S, Monciotti C, Tenconi R (1999). “Neurofibromatosis type 1 growth charts”. Am J Med Genet. 87 (4): 317–23. PMIDΒ 10588837.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]